KMT2A and acute lymphoblastic leukemia: While the majority of drugs did not affect the leukemia cell lines tested, approximately 12% of the compounds inhibited MLL-rearranged ALL cell viability by at least 20%, for both the Spectrum (Figure 1a) and Prestwick (Figure 1b) libraries.